Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Weiyan Medical

Explore full profile

A provider of infection precision medicine products and services

Dongcheng District, ChinaFounded 2019Biotech & Life Sciences
Valuation $100–250M Last recorded · 2023
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Weiyan Medical and the history behind them.

About Weiyan Medical

WillingMed Technology (Beijing) Co., Ltd., operating as Weiyan Medical, was established in 2019 by a team with extensive experience in pathogen detection. The founders, including CEO Zhang Yan and CTO Dr. Gai Wei, have backgrounds from institutions like Tsinghua University and the Chinese Academy of Sciences and have been deeply involved in the field for nearly two decades. Dr. Zhang has a long history in R&D and clinical application of advanced technologies, while Dr. Gai has focused on the precise molecular diagnosis of infectious pathogens for over a decade. Their collective experience in in-vitro diagnostic product development and management spurred the creation of Weiyan Medical to address challenges in clinical infection diagnostics.

The company operates in the precision molecular diagnostics market, specifically targeting infectious diseases. Its primary clients are large-scale hospitals, serving departments such as infectious diseases, respiratory, pediatrics, and intensive care units (ICU). Weiyan Medical generates revenue by providing diagnostic services and products, including the development, production, and sale of reagent kits and automated equipment. The business integrates scientific research, medical testing, and equipment manufacturing, with several regional testing centers in cities like Beijing, Hangzhou, and Guangzhou.

Weiyan Medical's core offering revolves around metagenomic next-generation sequencing (mNGS) to identify a wide array of pathogens from clinical samples. A key product is the PIseq-pathogen metagenome detection service, which can identify over 24,000 types of microorganisms, including bacteria, fungi, and viruses, delivering reports within 20 hours. For respiratory samples, the company developed a combined DNA+RNA pathogen detection process, which helps reduce testing costs. For more challenging blood samples, they introduced a highly sensitive dual-dimension blood infection detection product. To streamline the complex mNGS workflow, Weiyan Medical offers the WYHAW High-Throughput Automatic Workstation, a system designed to automate the entire process from sample preparation and library construction to data analysis and report generation, thereby reducing manual labor and improving safety and efficiency in clinical labs.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Dongcheng District, China
Open positions
None listed
Dealroom signal
18.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
b2b
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Apr 2023 $28M $110M Haier Capital · Galaxy Innovation Capital · Hunan Pharmaceutical Development Private Equity Fund ↗
SERIES AOther financing Nov 2021 $14M $55M Shanghai Lianhe Investment —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Weiyan Medical website traffic

Latest recorded traffic for Weiyan Medical is 0 monthly website visits, down 100% over the last three months.

Latest monthly visits0 3-month web change-100%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Shanghai Lianhe Investment
  • Haier Capital
  • Galaxy Innovation Capital
  • Hunan Pharmaceutical Development Private Equity Fund
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Dongcheng District HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Weiyan Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Weiyan Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.